Human gamma globulin enhances the survival of renal allografts.
Ninety seven transplant recipients participated in a controlled, clinical trial measuring the graft-enhancing property of a human gamma globulin preparation. The latter was prepared from the blood of pregnant women (RPGG) and contained antibodies with specificities for HLA locus products. Data analysis indicated that RPGG treated recipients had enhanced survival rates of their grafts if they had received one or more blood transfusions prior to transplantation.
D000961:Antilymphocyte Serum; D001803:Blood Transfusion; D002102:Cadaver; D003165:Complement System Proteins; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D016030:Kidney Transplantation; D008297:Male; D010920:Placenta; D011247:Pregnancy; D014184:Transplantation, Homologous; D005719:gamma-Globulins / Q000494:pharmacology*
D000961:Antilymphocyte Serum; D005719:gamma-Globulins; D003165:Complement System Proteins